ReviewTherapeutic advances in respiratory disease
Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.
Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- A systematic review on impact of SARS-CoV-2 infection.Microbiological research · 2023Pooled it
- Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- COVID-19 prophylaxis with doxycycline and zinc in health care workers: a prospective, randomized, double-blind clinical trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Trial
- Article
- Exploring the key structural attributes and chemico-biological interactions of pyridinone-based SARS-CoV-2 3CLHeliyon · 2024Article
- Review
- Article
- Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2023Review
- Green ecofriendly electrochemical sensing platform for the sensitive determination of doxycycline.Heliyon · 2023Article
- Antibiotic Utilization during COVID-19: Are We Over-Prescribing?Antibiotics (Basel, Switzerland) · 2023Article
- Role of the extracellular matrix in COVID-19.World journal of clinical cases · 2023Review
- Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy.Journal of clinical medicine · 2022Article
- Validation of a noninvasive aMMP-8 point-of-care diagnostic methodology in COVID-19 patients with periodontal disease.Clinical and experimental dental research · 2022Article
- Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications.Inflammopharmacology · 2022Review
- Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implications.Asian journal of psychiatry · 2022Review
- Shared Inflammatory Pathology of Stroke and COVID-19.International journal of molecular sciences · 2022Review
- Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications.Expert opinion on investigational drugs · 2022Article
- Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review.Journal of infection and public health · 2022Review
- The clinical association between Periodontitis and COVID-19.Clinical oral investigations · 2022Article
- Structural biology of SARS-CoV-2: open the door for novel therapies.Signal transduction and targeted therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.